Immune checkpoint inhibitor (ICI) treatment aims to block the PD1–PDL1 interaction with therapeutic monoclonal antibodies, e.g., pembrolizumab or nivolumab that blocks PD1, thereby removing the brake from the immune system and unleashing immune reactivity by tumor-reactive T cells. This evidence concerns the gene CD274 and neoplasm.